The IGF2BP1 Knockout HT29 Polyclonal Cells product comprises a polyclonal population of HT29 cells genetically modified by CRISPR/Cas9-mediated disruption of the IGF2BP1 gene. This loss-of-function model enables investigation of IGF2BP1-dependent post-transcriptional regulation without relying on transient knockdown methods. The polyclonal format preserves population-level heterogeneity while providing stable disruption of target gene expression, making it suitable for long-term functional studies and drug screening applications.
The HT29 cell line originates from a 44-year-old female with colorectal adenocarcinoma and harbors oncogenic BRAF V600E and TP53 mutations, capturing key genetic drivers of colorectal tumorigenesis. HT29 cells exhibit adherent epithelial morphology and retain the capacity to differentiate into enterocyte-like cells, expressing intestinal markers. These features render HT29 a widely employed model for studying intestinal permeability, drug transport, and colorectal cancer biology, particularly in the context of Wnt/??-catenin and MAPK pathway alterations.
IGF2BP1 encodes an oncofetal RNA-binding protein that recognizes m6A-modified mRNAs, thereby stabilizing oncogenic transcripts and enhancing their translation. Key downstream targets stabilized by IGF2BP1 include MYC, IGF2, and CD44 mRNAs, which promote cell proliferation, migration, and survival. IGF2BP1 function is regulated by upstream signals, such as MYC and the ??-catenin/TCF complex downstream of Wnt activation, as well as HIF1?? under hypoxic conditions. In the Wnt pathway, WNT3A binding to FZD receptors activates DVL, leading to stabilization of CTNNB1, which partners with TCF4 to induce MYC transcription. MYC protein subsequently drives IGF2BP1 expression, creating a positive feedback loop. Additionally, IGF2BP1 contributes to PI3K/AKT/mTOR signaling by stabilizing IGF2 mRNA, which encodes a ligand for IGF1R that activates IRS1, PIK3CA, and AKT1. IGF2BP1 also interacts with the RNA exosome complex and m6A reader proteins YTHDF1?C3, and cooperates with HNRNPA2B1 and AGO2 in RNA processing, illustrating its central role in post-transcriptional gene regulation.
In HT29 colorectal cancer cells, IGF2BP1 plays a critical role in maintaining the oncogenic phenotype by post-transcriptionally upregulating key driver genes. Disruption of IGF2BP1 is predicted to reduce the stability of MYC and IGF2 transcripts, thereby impairing proliferation and survival signaling via the PI3K/AKT/mTOR axis and attenuating Wnt/??-catenin-driven transcription. Given the BRAF V600E mutation in HT29 cells, this knockout model provides a relevant genetic background for dissecting how IGF2BP1 cooperates with MAPK pathway hyperactivation to promote tumor progression. Consequently, the IGF2BP1 knockout HT29 cells serve as a powerful tool for studying the interplay between RNA-binding proteins and oncogenic signaling networks in colorectal cancer.
Researchers can employ this polyclonal knockout population for a broad range of applications including cancer biology, RNA metabolism, and post-transcriptional regulation studies. Typical assays include RT-qPCR and Western blotting to confirm target disruption, proliferation (MTT/BrdU) and migration (Transwell) assays to assess functional consequences, and apoptosis detection (Annexin V) to evaluate survival effects. The model is also suitable for RNA immunoprecipitation (RIP) and dual-luciferase reporter assays to probe direct mRNA interactions, as well as RNA-seq for transcriptome-wide analysis. Additionally, the cells can be utilized in drug target validation and biomarker research, especially in screening drug responses in a BRAF-mutant colorectal cancer background. For technical details and ordering information, please contact Ascent Research.
